TRDA Institutional Ownership

Entrada Therapeutics, Inc.

Latest close $7.06 as of Aug 5, 2026

Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices. Form 13F rows are quarter-end holding context only and do not establish an exact entry date.

Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes. Filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro. The overall institutional consensus preview remains public. Compare plans.

Cross-institution intelligence

Institutional Research

Each institution is compared with its own prior filing, then the latest institution-level directions are compared for breadth.

Latest filing Nov 14, 2025

Public consensus preview Reduction leaning 30/100 institutional research score

1 tracked institution Latest filing Nov 14, 2025

1 reducing across 1 comparable institution.

Accumulating0

Unchanged0

Reducing1

Exited0

The overall consensus is public. Detailed holder comparisons, breadth history, ownership charts, and filing-specific signal analysis remain part of Investor and Pro research.

Price context

52-week position is market context and does not change the institutional consensus score.

52-week low$4.93 52-week high$21.79

Latest close $7.06 12.6% through the range

Tracked institutions

Public holder names and filing freshness. Detailed institution-by-institution analysis is locked.

Latest observation Sep 30, 2025

T. Rowe Price Associates Nov 14, 2025 filed

Detailed institutional research

See what is driving the consensus.

Unlock holder-by-holder changes, ownership history, breadth by period, disclosure timing, and filing-specific signal analysis.

Create free account Compare Investor and Pro

A free account adds watchlists and reveals tracker research gauges. Investor or Pro unlocks the detailed research above.

Beneficial ownership filing history

Showing 3 of 3 parsed filing(s)

Holder	Observed / filed	Reported change	Shares	Ownership	Observation	Filing	Latest
T. Rowe Price Associates CIK0000080255	Sep 30, 2025 observed Nov 14, 2025 filed · 45d Schedule 13G amendment	Reported reduction	360.5K -2.2M	12.00% 0.00 pts	$5.80	$8.75	$7.06
T. Rowe Price Associates CIK0000080255	Jun 30, 2025 observed Aug 14, 2025 filed · 45d Schedule 13G amendment	Reported reduction	2.6M -482.1K	12.00% +3.80 pts	$6.72	$5.25	$7.06
T. Rowe Price Associates CIK0000080255	Sep 30, 2024 observed Nov 14, 2024 filed · 45d Schedule 13G amendment	Earliest Schedule 13G amendment found	3.0M	8.20%		$19.04	$7.06

Explore more institutional activity

Related research

Crawlable links to other securities with similar institutional consensus or recent multi-institution accumulation.

Similar research strength

SBET SHARPLINK INC 30/100 Reduction leaning USFD US FOODS HOLDING CORP 30/100 Reduction leaning YETI YETI HOLDINGS INC 30/100 Reduction leaning HAIN HAIN CELESTIAL GROUP INC 30/100 Reduction leaning

Recent multi-institution accumulation

TVTX Travere Therapeutics, Inc. 2 accumulating Aug 6, 2026 PCVX VAXCYTE INC 2 accumulating Aug 6, 2026 VVX V2X INC 2 accumulating Aug 6, 2026 VSEC VSE CORP 3 accumulating Jul 31, 2026